Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer демонстрирует смешанную картину по фундаментальным показателям. С одной стороны, компания имеет низкие мультипликаторы P/E и P/B по сравнению с отраслевой медиацией, что может указывать на недооцененность. Однако, учитывая, что P/E ниже медианы на 35.3%, это может свидетельствовать о рисках, связанных с ростом прибыли в будущем. С другой стороны, компания показывает сильные результаты по доходам и чистой прибыли, значительно превышая медианные значения по отрасли. Показатели маржи также выше, что свидетельствует о сильной операционной эффективности. Однако, долговая нагрузка компании выше медианной, что вызывает опасения по поводу финансовой устойчивости. Дивиденды остаются стабильными, что является положительным знаком для акционеров. В целом, несмотря на некоторые сильные стороны, такие как высокий уровень выручки и прибыльности, присутствуют риски, связанные с долгами и низкими мультипликаторами, которые могут оказать негативное влияние на будущую оценку компании.

Pfizer, Inc.

The NASDAQ 100 After Hours Indicator is down -46.83 to 27,140.15. The total After hours volume is currently 123,882,886 shares traded.
The following are the most active stocks for the after hours session:
NVIDIA Corporation (NVDA) is -0.2499 at $209.01, with 4,952,801 shares traded. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
Walmart Inc. (WMT) is -0.02 at $127.99, with 4,930,628 shares traded. As reported by Zacks, the current mean recommendation for WMT is in the "buy range".
Apple Inc. (AAPL) is unchanged at $270.17, with 4,189,325 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2026. The consensus EPS forecast is $1.92. AAPL is scheduled to provide an earnings report on 4/30/2026, for the fiscal quarter ending Mar2026. The consensus earnings per share forecast is 1.92 per share, which represents a 165 percent increase over the EPS one Year Ago
Pfizer, Inc. (PFE) is +0.0226 at $26.28, with 4,143,914 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2026. The consensus EPS forecast is $0.68. PFE is scheduled to provide an earnings report on 5/5/2026, for the fiscal quarter ending Mar2026. The consensus earnings per share forecast is 0.74 per share, which represents a 92 percent increase over the EPS one Year Ago
Amazon.com, Inc. (AMZN) is -0.6123 at $262.43, with 3,998,635 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2026. The consensus EPS forecast is $1.96. Smarter Analyst Reports: Amazon Expects FTC’s Verdict on MGM Acquisition by Mid-March: Report
Wells Fargo & Company (WFC) is unchanged at $81.51, with 3,658,956 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2026. The consensus EPS forecast is $1.85. As reported by Zacks, the current mean recommendation for WFC is in the "buy range".
Intel Corporation (INTC) is -0.08 at $94.67, with 3,513,061 shares traded. Over the last four weeks they have had 10 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2026. The consensus EPS forecast is $0.1. , following a 52-week high recorded in today's regular session.
Nokia Corporation (NOK) is +0.02 at $12.48, with 3,203,503 shares traded., following a 52-week high recorded in today's regular session.
Cleveland-Cliffs Inc. (CLF) is +0.07 at $10.32, with 2,939,365 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2026. The consensus EPS forecast is $0.08. CLF's current last sale is 103.2% of the target price of $10.
EchoStar Corporation (SATS) is unchanged at $119.78, with 2,741,098 shares traded. As reported by Zacks, the current mean recommendation for SATS is in the "buy range".
Coca-Cola Company (The) (KO) is unchanged at $78.87, with 2,565,312 shares traded. As reported by Zacks, the current mean recommendation for KO is in the "buy range".
VICI Properties Inc. (VICI) is +0.12 at $28.72, with 2,233,899 shares traded. As reported by Zacks, the current mean recommendation for VICI is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

After Hours Most Active for Apr 29, 2026 : NVDA, WMT, AAPL, PFE, AMZN, WFC, INTC, NOK, CLF, SATS, KO, VICI

Key Points
Pfizer is slowly setting a strong foundation for the future through its deep pipeline and innovative qualities.
Medical Properties Trust is on a stronger footing following several challenges it encountered.
April has been a fairly volatile month for equities, and things may not settle down soon. Inflation is rising, and some experts are increasingly warning of a potential recession. In this environment, it helps to invest in dividend stocks. The passive income they provide can help smooth out market losses in case the recent economic and geopolitical challenges lead to a market crash. Even if that doesn't happen, reinvesting dividends is a great way to boost long-term returns. With that in mind, let's consider two high-yielding dividend stocks to consider this April: Pfizer (NYSE: PFE) and Medical Properties Trust (NYSE: MPT).
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
1. Pfizer
Pfizer boasts a juicy forward dividend yield of 6.4%. But between poor financial results and stiff competition in some areas, is it sustainable? In my view, it is. One of Pfizer's strengths is its deep portfolio of approved medicines. Even putting aside minor drugs or vaccines that make little revenue and don't meaningfully move the needle for the company, Pfizer had several drugs that generated over $1 billion in sales last year.
True, some of these will lose patent exclusivity soon. That's the case with Pfizer's anticoagulant, Eliquis. The company's coronavirus franchise is also not on solid footing. However, newer products will help it move beyond those issues. Pfizer's Abrysvo, a vaccine for the respiratory syncytial virus, was first approved in 2023. Last year, it generated about $1 billion in sales, up 37% year over year.
Elrexfio, a cancer drug approved in 2023, is also making progress. Last year, its revenue totaled $304 million, up from $103 million in 2024.
Pfizer's current crop of newer medicines likely won't be enough to replace older ones whose sales are already dropping or will start to decline in the next few years. But the company's rich pipeline will help address that problem. Pfizer has started plenty of phase 3 studies over the past couple of years, with more on the horizon.
The company should make significant clinical and regulatory progress through 2030. By then, Pfizer could have a much rejuvenated portfolio of approved medicines and much better financial results. The company hasn't cut its dividend despite the troubles it has encountered, and it is unlikely to do so soon, making it an attractive blue chip dividend stock.
2. Medical Properties Trust
Medical Properties Trust (MPT) is a healthcare-focused real estate investment trust (REIT). Over the past few years, the company has faced challenges, including some of its tenants defaulting on rent and going bankrupt. MPT made difficult but necessary decisions to deal with these issues. The company cut its dividend -- twice -- and sold some assets.
It also put new tenants in the facilities occupied by some of its older ones that went bankrupt. MPT emerged from this ordeal a more diversified company whose business is less likely to suffer significantly from the misfortunes of one or two tenants.
However, investors might still wonder whether the company's monster forward yield of 7% is safe, especially given the uncertain economic landscape we face. My view is that it is. Any REIT can face tenant rent defaults -- as MPT did -- but medical-focused REITs are arguably safer than many others, since healthcare is a defensive sector. MPT is unlikely to encounter the same challenges anytime soon. As evidence of the company's confidence in the recovery of its underlying business and its willingness to reward shareholders, MPT announced last year that it would increase its dividend.
MPT's rebound isn't complete. The stock is still down significantly over the past three years. However, the REIT is well-positioned to perform well over the long run as its business stabilizes. MPT is an attractive, high-yielding dividend stock for long-term income seekers.
Should you buy stock in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $492,752!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,327,935!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 28, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

2 High-Yielding Dividend Stocks to Buy for Passive Income in April

Pfizer (PFE) ended the recent trading session at $26.48, demonstrating a -1.16% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.49%. Meanwhile, the Dow lost 0.05%, and the Nasdaq, a tech-heavy index, lost 0.9%.
The drugmaker's shares have seen a decrease of 3.53% over the last month, not keeping up with the Medical sector's loss of 0.86% and the S&P 500's gain of 12.8%.
The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its earnings on May 5, 2026. In that report, analysts expect Pfizer to post earnings of $0.74 per share. This would mark a year-over-year decline of 19.57%. Alongside, our most recent consensus estimate is anticipating revenue of $13.82 billion, indicating a 0.77% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $2.98 per share and a revenue of $61.11 billion, demonstrating changes of -7.45% and -2.35%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.31% higher. Right now, Pfizer possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 8.98 right now. This valuation marks a discount compared to its industry average Forward P/E of 13.86.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 171, placing it within the bottom 30% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Why Pfizer (PFE) Dipped More Than Broader Market Today

Key Points
Pfizer's growth rate has tanked in recent years, and investors remain concerned about the future.
The company has been loading up on acquisitions to bolster its pipeline, but it could still be years before a payoff is evident.
The stock comes with risk, but its valuation is also incredibly low.
Pfizer (NYSE: PFE) has been a pharmaceutical giant for decades and a key player in healthcare. Its drugs have saved lives and generated a ton of revenue for its business over the years. While it's still innovating and developing new treatments, it's also facing adversity, with multiple drugs losing patent protection in the near future.
This makes the stock an intriguing option to consider today. It's down more than 30% over the past five years due to slowing growth and concerns about what lies ahead. There's some risk here, but there's also opportunity, given that its valuation has come down so much. And don't forget, the stock also pays a dividend, which, due to its rapid decline, now yields an incredible 6.4%.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Is the stock a buy, sell, or hold at $27?
Can Pfizer get back to growing its business?
Ultimately, whether or not Pfizer's stock can go on a prolonged rally will depend on the outlook growth investors have for the business. At a time when the healthcare sector is under pressure to reduce costs, and there's growing skepticism about vaccines, it's not all that surprising that investors aren't feeling all that excited about many healthcare stocks. Pfizer, which generates a lot of revenue from vaccines and which got a big boost from its COVID vaccine and pill in recent years, is certainly no exception.
Its struggles can be summed up with the chart below, which highlights just how impressive its growth rate was during the pandemic, and how quickly it came crashing back down.
Pfizer has been involved in many acquisitions in recent years in an effort to grow its business, but it's proving to be a challenging road ahead. A few years ago, CEO Albert Bourla outlined a growth strategy that leaned heavily on acquisitions and in-house development, through which Pfizer could add $25 billion to its top line by the end of the decade, more than offsetting a possible $18 billion decline in revenue due to growing competition from generics. Investors, however, don't appear to be convinced that it's on the right path.
Why Pfizer's stock might be worth the risk
Pfizer is navigating a challenging path ahead, but I believe its efforts will pay off. This is the healthcare sector after all, and it can sometimes take just one big drug approval that makes a stock a hot buy again. Pfizer isn't at that stage yet, but with over 100 drug candidates in its pipeline, odds are, it'll have more than a few approvals coming its way in the near future.
Plus, the stock's valuation is extremely low, offering investors a solid margin of safety. It trades at just nine times its expected future earnings (based on analyst estimates). That's a dirt cheap valuation for a company that generated $63 billion in revenue last year, and which could be on the cusp of much more growth. Investing in Pfizer comes with a bit of risk, but the stock also possesses a lot of potential upside in the long run.
Should you buy stock in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $492,752!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,327,935!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 28, 2026.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Should You Buy, Sell, or Hold Pfizer at $27?

(RTTNews) - Pfizer Inc. (PFE) on Tuesday said it has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla over patent litigation related to Vyndamax, its treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Under the agreements, the effective U.S. patent expiry for Vyndamax has been extended to June 1, 2031, subject to ongoing litigation outcomes. Pfizer had earlier expected a revenue decline beginning in 2029 due to patent expiry, but now anticipates relatively stable U.S. sales from 2028 through mid-2031.
Vyndamax remains the market leader in ATTR-CM treatment, accounting for about 75% of prescription volume. The once-daily therapy has demonstrated significant reductions in all-cause mortality and cardiovascular-related hospitalizations.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pfizer Settles Patent Disputes, Extends VYNDAMAX Exclusivity To 2031

Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on May 5, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of $0.74 per share in its upcoming report, which represents a year-over-year change of -19.6%.
Revenues are expected to be $13.82 billion, up 0.8% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1.73% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Pfizer?
For Pfizer, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -5.49%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Pfizer will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Pfizer would post earnings of $0.57 per share when it actually produced earnings of $0.66, delivering a surprise of +15.79%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Pfizer doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected Results
Among the stocks in the Zacks Large Cap Pharmaceuticals industry, Eli Lilly (LLY), is soon expected to post earnings of $7.26 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +117.4%. This quarter's revenue is expected to be $17.78 billion, up 39.7% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Lilly has been revised 2.8% up to the current level. Nevertheless, the company now has an Earnings ESP of -4.83%, reflecting a lower Most Accurate Estimate.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Lilly will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Should You Invest in Pfizer Inc. (PFE)?
Before you invest in Pfizer Inc. (PFE), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline

The NASDAQ 100 Pre-Market Indicator is down -350.87 to 26,954.81. The total Pre-Market volume is currently 163,195,631 shares traded.
The following are the most active stocks for the pre-market session:
NVIDIA Corporation (NVDA) is -7.56 at $209.05, with 10,044,906 shares traded., following a 52-week high recorded in prior regular session.
ProShares UltraPro QQQ (TQQQ) is -2.66 at $59.98, with 7,002,488 shares traded. This represents a 138.39% increase from its 52 Week Low.
Bed Bath & Beyond, Inc. (BBBY) is +1.61 at $6.95, with 5,803,402 shares traded. BBBY's current last sale is 86.88% of the target price of $8.
Leverage Shares 2X Long CRWV Daily ETF (CRWG) is -0.705 at $4.03, with 5,633,653 shares traded. This represents a 124.23% increase from its 52 Week Low.
ProShares UltraPro Short QQQ (SQQQ) is +2.24 at $54.69, with 5,182,007 shares traded. This represents a 4.43% increase from its 52 Week Low.
Direxion Daily TSLA Bull 2X ETF (TSLL) is -0.385 at $11.94, with 5,024,881 shares traded. This represents a 34.71% increase from its 52 Week Low.
Intel Corporation (INTC) is -3.4465 at $81.54, with 5,017,365 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2026. The consensus EPS forecast is $0.09. INTC's current last sale is 108.72% of the target price of $75.
Nokia Corporation (NOK) is -0.3332 at $10.38, with 4,657,527 shares traded. As reported by Zacks, the current mean recommendation for NOK is in the "buy range".
Pfizer, Inc. (PFE) is +0.825 at $27.62, with 3,297,418 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2026. The consensus EPS forecast is $0.68. PFE is scheduled to provide an earnings report on 5/5/2026, for the fiscal quarter ending Mar2026. The consensus earnings per share forecast is 0.74 per share, which represents a 92 percent increase over the EPS one Year Ago
Oracle Corporation (ORCL) is -13.05 at $159.91, with 3,225,730 shares traded. As reported by Zacks, the current mean recommendation for ORCL is in the "buy range".
Joby Aviation, Inc. (JOBY) is +0.191 at $9.23, with 1,800,918 shares traded.JOBY is scheduled to provide an earnings report on 5/5/2026, for the fiscal quarter ending Mar2026. The consensus earnings per share forecast is -0.21 per share, which represents a -18 percent increase over the EPS one Year Ago
Corning Incorporated (GLW) is -21.14 at $146.87, with 1,574,439 shares traded. As reported by Zacks, the current mean recommendation for GLW is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Apr 28, 2026 : NVDA, TQQQ, BBBY, CRWG, SQQQ, TSLL, INTC, NOK, PFE, ORCL, JOBY, GLW

Key Points
Bristol Myers Squibb's valuation metrics show the stock is a bona fide bargain.
However, valuation metrics can be misleading because most of them don't factor in growth.
The stock may not be the biggest bargain in Big Pharma, but it could still be attractive to income and value investors.
Every American knows that healthcare isn't cheap. Healthcare costs continue to rise. Some healthcare stocks are cheap, though, including the stocks of some of the world's biggest drugmakers.
Bristol Myers Squibb (BMS) (NYSE: BMY) is one of them. To be sure, BMS isn't the biggest pharma stock. Its market cap of around $120 billion ranks it just outside the top 10 largest drugmakers. But is BMS the best bargain in big pharma?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Some persuasive numbers
A quick look at BMS's valuation metrics might convince you that this stock is a bona fide bargain. For example, the average price-to-sales ratio for pharmaceutical companies is around 4.4. BMS's shares trade at only 2.5 times sales.
The company's bottom line appears to scream "bargain", too. BMS's forward price-to-earnings ratio is a low 9.4. The healthcare sector's average forward earnings multiple is 17.3.
Some investors prefer to use enterprise value (EV) to value companies because it accounts for debt. BMS's EV/EBITDA multiple of 10.3 also looks attractive compared to most other drugmakers. Lilly is super-expensive with its EV/EBITDA of around 27. AbbVie (NYSE: ABBV), AstraZeneca (NYSE: AZN), and Johnson & Johnson (NYSE: JNJ) also sport much higher EV-based multiples than BMS.
What about a deeper dive into BMS's valuation? At least one discounted cash flow model estimates that the pharma stock is significantly undervalued, with an upside of roughly 40%.
Valuation metrics can be misleading
BMS looks like a value stock from nearly every angle. However, valuation metrics can be misleading. Specifically, most of them don't account for a company's growth prospects over the next several years. Unfortunately, BMS's growth will almost certainly slow drastically.
The company faces a daunting patent cliff. U.S. patents for blood thinner Eliquis and cancer immunotherapy Opdivo expire in 2028. Last year, Eliquis was BMS's top-selling drug, while Opdivo ranked No. 2. Their combined sales make up nearly half of the company's total revenue.
BMS won't have to wait until its top two blockbusters lose exclusivity to encounter problems. Cancer drugs Abraxane, Pomalyst, Revlimid, and Sprycel have already lost patent exclusivity. The company expects revenue to decrease slightly this year compared to 2025.
Stocks are usually cheap for a reason. BMS is no exception. Investors have given the stock a low valuation because they know the growth prospects aren't appealing over the rest of the decade.
Granted, BMS has a promising growth portfolio that includes cancer drug Opdualag, autoimmune disease drug Sotyktu, and heart disease drug Camzyos. Combined sales from all of the drugs in the company's growth portfolio rose 17% year over year in 2025. However, BMS's legacy drugs still comprise roughly 45% of revenue.
The biggest bargain in big pharma?
Probably the best argument against Bristol Myers Squibb being the biggest bargain in big pharma is that several other stocks have even lower valuation metrics. Pfizer (NYSE: PFE), for example, boasts a lower forward P/E multiple of 9.1. Factoring in growth projections over the next five years, AbbVie looks more attractively valued.
However, BMS doesn't have to be the biggest bargain in big pharma to still be a good pick for some investors. Many income investors will love the company's forward dividend yield of 4.3% and its record of increasing dividends for 17 consecutive years. A lack of growth won't be as concerning to most income investors. As long as BMS can keep the dividends flowing, they'll be happy.
Some value investors may still find BMS appealing, especially those with long investment horizons. The company's growth portfolio should steadily generate a larger share of its revenue. BMS CEO Chris Boerner believes that his company has "the potential to achieve industry-leading, sustainable growth into the 2030s and beyond." If you're willing to wait, BMS could deliver solid total returns.
Should you buy stock in Bristol Myers Squibb right now?
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 27, 2026.
Keith Speights has positions in AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool has positions in and recommends AbbVie, AstraZeneca Plc, Bristol Myers Squibb, and Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is Bristol Myers Squibb the Best Bargain in Big Pharma?

Key Points
This company is involved in technology, retail, entertainment, medical services, and more.
It could become the go-to destination for individuals seeking GLP-1 treatments.
One particular type of drug has become a household name in recent times, and that's a class known as GLP-1. Originally approved for type 2 diabetes, these drugs also showed strengths in weight loss -- and that led to a surge in off-label prescriptions for this indication. Later, drugmakers won approval of these drugs specifically for weight loss.
Today, Eli Lilly and Novo Nordisk dominate the GLP-1 drug market, selling Zebound and Wegovy, respectively. These are injectables, but Lilly and Novo recently earned the regulatory nod for oral drugs -- Lilly now offers Foundayo, while Novo sells oral Wegovy.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
These treatments have generated blockbuster revenue for the companies, and rivals, from biotech Viking Therapeutics to pharma giant Pfizer, are developing candidates and hope to eventually join them in this valuable market -- one forecast to approach $100 billion by the end of the decade. But is it possible that the next potential winner in the GLP-1 market may actually be a tech player? Let's find out.
From e-commerce to publishing
This particular tech company is actually involved in a variety of industries, from e-commerce, publishing, and entertainment to physical grocery stores. I'm talking about Amazon (NASDAQ: AMZN) -- and one of the company's focuses in recent years has been on carving out a spot in the healthcare industry.
Today, Amazon One Medical and Amazon Pharmacy do just this -- the former offers both virtual and in-person medical appointments, while the latter allows patients to easily order prescriptions online. And now, Amazon is using these strengths to launch a new service that addresses the needs of patients who want to lose weight.
Amazon One Medical just announced a weight management program centered around GLP-1 treatment. The program views obesity as a chronic condition, offering patients a comprehensive offering tailored to their specific needs -- and integrating the weight loss journey into the patient's overall healthcare journey at Amazon One Medical. Patients turn to the service for pre-visit screening, prescriptions, follow-up consultations, and more. And all of this leverages the network Amazon has already built, including in-person and virtual medical care, pharmacy, and fast delivery of prescription drugs.
Through the program, patients can order popular GLP-1 medicines, including the latest launches Foundayo and oral Wegovy. Prices are on par with what is generally available elsewhere, but patients benefit from the convenience of organizing their entire weight loss program through Amazon One Medical -- and existing patients will like the promise of 24/7 prescription renewals. Another plus that may appeal to patients: Amazon says all medications are available for "fast delivery" throughout the U.S., and same-day delivery, now happening in almost 3,000 cities, is set to expand its reach.
How Amazon may benefit from the GLP-1 boom
Now, let's consider our question: Could Amazon be the next big winner in the GLP-1 boom? This will depend on the number of patients who decide to choose Amazon to accompany them on the weight loss path. Amazon generates revenue through Amazon One Medical membership fees, as well as through certain visits and medical and pharmacy services. So its well-developed ecosystem of healthcare services could deliver growth if demand for the weight management program takes off.
There's reason to be optimistic about this program's potential due to the high demand for GLP-1 drugs -- and the fact that, at times, patients have had difficulty accessing these treatments. If Amazon makes it easy and convenient for them, the company may become the go-to destination for many patients.
Of course, given the revenue levels generated by Amazon's biggest profit driver, its cloud computing business, I don't expect GLP-1 drugs to become a massive growth engine for the entire company. Amazon Web Services (AWS), the cloud business, recently reached a $142 billion annual revenue run rate. That said, the weight loss program could become a significant driver for Amazon One Medical's growth -- and make Amazon one of the long-term winners in the growing GLP-1 market.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $540,224!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $51,615!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $498,522!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom?

Key Points
Pfizer isn't hitting on all cylinders today, and Wall Street is clearly worried about the future.
A deep stock price decline has pushed the dividend yield up to 6.3%, which management says it plans to support.
Shares of Pfizer (NYSE: PFE) have fallen 55% from their late 2021 high. That decline highlights a material change in Wall Street's view of the pharmaceutical giant. And it has pushed the dividend yield up to a lofty 6.3%. Is the dividend actually sustainable? Here's what you need to know.
What's wrong with Pfizer?
There's actually nothing unusual going on with Pfizer's pharmaceutical business. The industry is highly competitive, capital-intensive, and driven by innovation. Unfortunately, research and development outcomes aren't predictable. Sometimes things don't work out as well as planned.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
That's one big knock against the company today, given that its internally developed GLP-1 weight-loss drug candidate had to be abandoned. GLP-1 drugs are the hot topic on Wall Street, and Pfizer isn't even in the game yet.
The negative investor sentiment surrounding Pfizer's GLP-1 situation added to the vaccine issues the company was already facing. Part of a stock price rally up until late 2021 was driven by investors excited by the company's COVID vaccine opportunity. While vaccine sales were very strong for a short period, the long-term opportunity proved less robust than expected, and they haven't been a strong point for Pfizer.
There are very good reasons for investors to be downbeat about Pfizer right now. However, the deep drawdown in the stock is really a mix of current pessimism following what now appears to be too much enthusiasm. Pfizer, with a $155 billion market cap, is still a large and innovative healthcare giant.
Pfizer is investing for the future
As noted, you can't predict research outcomes. But given Pfizer's long and successful history, it seems highly likely that it will eventually develop new and innovative drugs. Notably, it quickly shifted gears in the GLP-1 space, buying a company with an attractive GLP-1 drug candidate and partnering with another company to distribute its GLP-1 drug if it gets approved. It is also pushing forward with oncology and migraine drugs, since weight-loss is only one of the many areas on which the company is focused.
Meanwhile, the company is being very clear about the dividend. Pfizer's full-year 2025earnings callpresentation includes a forward-looking slide that prominently states a long-term goal of maintaining the dividend.
There's just one small wrinkle here. The trailing 12-month dividend payout ratio ended 2025 at 126%. That's normally a warning sign for dividend investors, but you have to take it with a grain of salt. Dividends are paid out of cash flows, not earnings. The cash dividend payout ratio is a bit lower at 107%. That's clearly still over 100%, which is a problem. However, companies can support a dividend by increasing debt over short periods.
The real question is the dedication of the company's board of directors to maintaining the dividend. There's no way to know about that commitment, but given management's strong statement on the dividend, it seems likely the board isn't considering cutting the payment any time soon.
There's always a risk
The average pharmaceutical stock yields 1.7%. It is very clear that Pfizer's yield is multiples of that because there's a risk that its dividend could be cut. A quick examination of the payout ratio is ample proof of that risk. And the company's recent business results aren't supportive, either. And yet, Pfizer remains a large and innovative company that continues to focus on developing new drugs.
It seems highly likely that Pfizer gets back on track. And given management's current statements about backing the dividend, more aggressive dividend investors should probably feel reasonably confident that the dividend will be supported until the company's research efforts start to pay off.
Should you buy stock in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 25, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.